Virtual control groups (VCGs) are gaining attention as a way to reduce reliance on traditional concurrent controls in preclinical toxicology. Anchored in experience from the European Innovative Health Initiative (IHI) project VICT3R, this webinar brings together consortia, industry, and regulatory perspectives to support engagement in this emerging area.
During this webinar, our panelists will:
- Provide an introduction to VCGs and the current landscape
- Share early lessons learned from the IHI VICT3R project
- Discuss scientific and regulatory considerations for future adoption
Panelists:
- William Houser, Scientific Associate Director, Nonclinical Safety, Bristol-Myers Squibb
- Karolina Kopanska, Postdoctoral Toxicologist, Johns Hopkins Center for Alternatives to Animal Testing (CAAT)
- Lars Mecklenburg, Executive Director, Data & Science, Labcorp Early Development
- Lilliam Rosario, Program Director, TransCelerate
- Thomas Steger-Hartmann, Senior Project Lead, Innovative Health Initiative; VP, Bayer AG